- Home
- NKTR vs JCE Comparison
NKTR vs JCE Comparison
Compare NKTR & JCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NKTR | JCE |
|---|---|---|
| Founded | 1990 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 905.0M | 269.8M |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | NKTR | JCE |
|---|---|---|
| Price | $42.25 | $15.97 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $111.83 | N/A |
| AVG Volume (30 Days) | ★ 966.4K | 49.7K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.26% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $62,600,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.48 | $11.64 |
| 52 Week High | $66.92 | $14.28 |
Technical Indicators
Market Signals| Indicator | NKTR | JCE |
|---|---|---|
| Relative Strength Index (RSI) | 36.05 | 51.64 |
| Support Level | $41.32 | $15.94 |
| Resistance Level | $44.91 | $16.14 |
| Average True Range (ATR) | 3.59 | 0.17 |
| MACD | -0.66 | 0.02 |
| Stochastic Oscillator | 5.85 | 64.71 |
Price Performance
Historical ComparisonAbout NKTR Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
About JCE Nuveen Core Equity Alpha Fund of Beneficial Interest
Nuveen Core Equity Alpha Fund is a diversified closed-end management investment company. Its investment objective is to provide an attractive level of total return, through long-term capital appreciation and through income and gains. The Fund invests in a portfolio of actively managed large-capitalization U.S. common stocks, using the sub-adviser's proprietary quantitative process designed to provide the potential for long-term outperformance. Additionally, the Fund seeks to reduce the volatility of its returns relative to the returns of the Equity Portfolio over extended periods by writing (selling) index call options and/or call options on custom baskets of securities.